In the Japanese pharmaceutical industry, there were 16 M&A deals announced in Q3 2023, worth a total value of $498.7m, according to GlobalData’s Deals Database. The $466.1m acquisition of Idorsia Pharmaceuticals Japan and Idorsia Pharmaceuticals Korea by Sosei Group was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in Japan increased by 65% in Q3 2023 compared with the previous quarter’s total of $302.1m and rose by 13343% as compared to Q3 2022. Related deal volume decreased by 16% in Q3 2023 versus the previous quarter and was 7% higher than in Q3 2022.
The top-ranked legal advisorss supporting these M&A deals in Japan Q3 2023 were Cravath, Swaine & Moore; Nishimura & Asahi with 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.